News Australian Investor Online - LCT beginning clinical trials The trials are designed according to FDA guidelines and monitored by a Boston based Contract Research Organisation. DiabeCell is a pig pancreatic cell product for the treatment of insulin dependent Diabetes. The natural neo-natal pig islet cells are encased in capsules that allow insulin to be released but prevent the patient’s immune system from attacking the cells. The islets are simply injected into the body and produce insulin as needed in response to the levels of glucose in the blood. This mimics the normal insulin release that occurs in healthy non-diabetic people and thus helps regulate blood glucose levels in those suffering from type1 diabetes. The trial may enable an expedited route to commercialization within the region. Initial response to treatment will be evident within six months. The trial will use cells from fully screened and biocertified pigs, bred according to United States FDA guidelines. Click on the link below to access the full text: |